Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00419796 · ClinicalTrials.gov registry record · Phase 4
Effects of Lumiracoxib and Ibuprofen on Blood Pressure and Urinary Eicosanoid Excretion in Osteoarthritis Patients With Controlled Hypertension
A Phase 4 study, sponsored by Novartis.
- Completed
- Registry status
- Phase 4
- Development phase
- 78
- Enrollment target
NCT00419796 is a Phase 4 study that has completed, run by Novartis. The registered enrollment target is 78 participants.
The verdict
NCT00419796, a Phase 4 study, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 78 participants
- Enrollment target
Study Summary
This randomized study will compare the effect of lumiracoxib, ibuprofen and placebo on 24-hour blood pressure profile and on urinary excretions of eicosanoids in controlled hypertensive patients who have osteoarthritis.
Interventions
- DRUG Lumiracoxib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 78 participants |
| Start Date | 2006-11 |
| Est. Completion | 2007-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00419796
The ClinicalTrials.gov registry entry for NCT00419796 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 78 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Lumiracoxib is the first listed.
NCT00419796 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00419796 about?
NCT00419796 is a clinical study titled "Effects of Lumiracoxib and Ibuprofen on Blood Pressure and Urinary Eicosanoid Excretion in Osteoarthritis Patients With Controlled Hypertension". This randomized study will compare the effect of lumiracoxib, ibuprofen and placebo on 24-hour blood pressure profile and on urinary excretions of eicosanoids in controlled hypertensive patients who have osteoarthritis.
What is the current status of trial NCT00419796?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 78 participants. The study started on 2006-11. Estimated completion is 2007-09.
What interventions are being tested in trial NCT00419796?
The interventions under investigation include: Lumiracoxib (DRUG).
Who is sponsoring clinical trial NCT00419796?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.